Skip to main content
Our Story

Welcome to

Alpha Anomeric

We are developing the next generation of oligonucleotide therapeutics with improved safety and precision.

Alpha Anomeric

Bicyclo DNA

Modulation of RNA holds the promise for opening up entirely new concepts for pharmaceutical intervention. Providing the precision tools to modulate this wealth of new RNA targets is our mission.

Our proprietary alpha anomeric-bicyclo DNA platform reaches unprecedented precision in RNA modulation by eliminating common side effects of current oligonucleotide chemistries and by increasing the specificity and effectiveness of treatment.

Eliminating common side effects

All state-of-the-art oligonucleotide chemistries require a modification of the natural phosphodiester linkage found in DNA and RNA in order to prevent rapid degradation by nucleases that are present in all biological fluids.

Increasing specificity and efficacy

The Watson Crick base pairing mechanism allows for the design of highly specific compounds for interference with RNA, which are called oligonucleotides.

Latest News

26th November 2021 in Company News

7′,5′-alpha-bicyclo-DNA: new chemistry for oligonucleotide exon splicing modulation therapy

Alpha Anomeric Président, Dr. Wolfgang Renner, Nucleic Acids Research Published: 26 November 2021 An excerpt from the research paper can…
Read More
Find Out More
Get in touch with us to find out more about what we do

© 2018 Alpha Anomeric | All Rights Reserved